Real-World Treatment Patterns and Outcomes of First-Line Immunotherapy Among Patients With Advanced Nonsquamous NSCLC Harboring BRAF, MET, or HER2 Alterations by Garassino, Marina C., MD, Oskar, Sabine, PhD, MPH, Arunachalam, Ashwini, MPH, BDS, Zu, Ke, PhD, ScD, MPH, Kao, Yu-Han, PhD, Chen, Cai, PhD, Meng, Weilin, MEng, Pietanza, M. Catherine, MD, Zhao, Bin, MD, Aggarwal, Himani, MPhil, PhD

Get full text

Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC by Kim, Hye Ryun, MD, PhD, Awad, Mark M., MD, PhD, Navarro, Alejandro, MD, Gottfried, Maya, MD, Peters, Solange, MD, PhD, Csőszi, Tibor, MD, Cheema, Parneet K., MD, Rodriguez-Abreu, Delvys, MD, PhD, Wollner, Mirjana, MD, Yang, James Chih-Hsin, MD, PhD, Mazieres, Julien, MD, PhD, Orlandi, Francisco J., MD, Luft, Alexander, MD, PhD, Gümüş, Mahmut, MD, Kato, Terufumi, MD, Kalemkerian, Gregory P., MD, Luo, Yiwen, PhD, Santorelli, Melissa L., PhD, MPH, Pietanza, M. Catherine, MD, Rudin, Charles M., MD, PhD

Get full text

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC by Garassino, Marina C., MD, Gadgeel, Shirish, XX, Novello, Silvia, XX, Halmos, Balazs, XX, Felip, Enriqueta, XX, Speranza, Giovanna, XX, Hui, Rina, XX, Garon, Edward B., XX, Horinouchi, Hidehito, XX, Sugawara, Shunichi, XX, Rodriguez-Abreu, Delvys, XX, Reck, Martin, XX, Cristescu, Razvan, XX, Aurora-Garg, Deepti, XX, Loboda, Andrey, XX, Lunceford, Jared, XX, Kobie, Julie, XX, Ayers, Mark, XX, Piperdi, Bilal, XX, Pietanza, M. Catherine, XX, Paz-Ares, Luis, XX

Get full text

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial by Antonia, Scott J, Prof, López-Martin, José A, MD, Bendell, Johanna, MD, Ott, Patrick A, MD, Taylor, Matthew, MD, Eder, Joseph Paul, MD, Jäger, Dirk, MD, Pietanza, M Catherine, MD, Le, Dung T, MD, de Braud, Filippo, Prof, Morse, Michael A, Prof, Ascierto, Paolo A, MD, Horn, Leora, MD, Amin, Asim, MD, Pillai, Rathi N, MD, Evans, Jeffry, Prof, Chau, Ian, MD, Bono, Petri, MD, Atmaca, Akin, MD, Sharma, Padmanee, Prof, Harbison, Christopher T, PhD, Lin, Chen-Sheng, PhD, Christensen, Olaf, MD, Calvo, Emiliano, Dr

Get full text

Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer... by Garassino, Marina C, MD, Gadgeel, Shirish, MBBS, Esteban, Emilio, MD, Felip, Enriqueta, PhD, Speranza, Giovanna, MD, Domine, Manuel, PhD, Hochmair, Maximilian J, PhD, Powell, Steven, MD, Cheng, Susanna Yee-Shan, MD, Bischoff, Helge G, MD, Peled, Nir, Prof, Reck, Martin, MD, Hui, Rina, PhD, Garon, Edward B, MD, Boyer, Michael, MD, Wei, Ziwen, PhD, Burke, Thomas, PhD, Pietanza, M Catherine, MD, Rodríguez-Abreu, Delvys, MD

Get full text

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study by Rudin, Charles M, Prof, Pietanza, M Catherine, MD, Bauer, Todd M, MD, Ready, Neal, Prof, Morgensztern, Daniel, MD, Glisson, Bonnie S, Prof, Byers, Lauren A, MD, Johnson, Melissa L, MD, Burris, Howard A, MD, Robert, Francisco, Prof, Han, Tae H, PhD, Bheddah, Sheila, BA, Theiss, Noah, MS, Watson, Sky, BS, Mathur, Deepan, MD, Vennapusa, Bharathi, MD, Zayed, Hany, PhD, Lally, Satwant, MS, Strickland, Donald K, MD, Govindan, Ramaswamy, Prof, Dylla, Scott J, PhD, Peng, Stanford L, MD, Spigel, David R, MD

Get full text

Novel Therapeutic Approaches for Small Cell Lung Cancer: The Future has Arrived by Pietanza, Maria Catherine, MD, Rudin, Charles M., MD, PhD

Get full text